InvestorsHub Logo
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

Re: Whosetosay post# 34179

Friday, 09/13/2013 11:08:53 PM

Friday, September 13, 2013 11:08:53 PM

Post# of 80490
About 20% present T315I in TKI-naive...

When randomized 50/50 this automatically reduces imatinib's MMR by half, or 10%, versus Pona. This also increases Pona's MMR by 7.5% since 75% of T315I patients achieved MMR in PACE trial.

So automatic 17.5% delta on MMR, and as you say throw in a few more of the 49 additional mutations shown to be resistant to imatinib but sensitive to Ponatinib and voila...its EPIC!







Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.